Asian Journal of Pharmaceutical Technology & Innovation
ISSN: 2347-8810

Review Article

Received on: 01-10-2014
Accepted on: 10-10-2014
Published on: 15-10-2014

Corresponding Author:

* Pramod Singh Khatri

Head of Department &
Programme Coordinator,
Clinical Research,
Amity Medical School,
Amity University ,
Haryana, India.

QR Code AJPTI

*Email Id-
pramodsinghkhatri@gmail.com

A molecular outlook of Ebola Virus Infection - Contemporary evidence and Future Implications

Pramod Singh Khatri[1], Kashish Agarwal[2]

ABSTRACT

A flare-up of EVD, which began in December 2013, is constantly advancing in Guinea, Liberia and Sierra Leone. The first instance was accounted for from Guéckédou prefecture, which is a forested locale of south-eastern Guinean earth outskirt with Liberia and Sierra Leone. After an ease off in April, the flare-up has quickened amid the last two months. This is the biggest EVD episode ever documented, both regarding number of cases and geographical area. It is additionally the first run through EVD has spread to larger urban societies.

Despite the fact that its clinical progression is well known, the particular mechanism underlying the pathogenicity of Ebola virus infection has not been obviously portrayed. This is expected to some degree, to the trouble in acquiring specimens and investigating the infection in the moderately remote regions in which the outbreaks happen. Also, a high level of biohazard regulation is needed for lab studies and clinical dissection. Segregation of the viral cDNAs and the development of expression framework shear permitted the investigation of Ebola virus infection under less restrictive conditions and encouraged an understanding of the mechanism underlying virally affected cell damage.

Key-words: Ebola virus disease, EBOV HF, Epidemic disease

Cite this article as:
Pramod Singh Khatri, Kashish Agarwal, A molecular outlook of Ebola Virus Infection - Contemporary evidence and Future Implications, Asian Journal of Pharmaceutical Technology & Innovation, 02 (08); 2014.

1 HOD, Clinical Research, Amity Medical School, Amity University, Haryana, India.
2 MSc.Clinical Research, Amity Medical School, Amity University, Haryana, India.

Introduction:-

EVD, earlier known as Ebola hemorrhagic fever, is an extreme, frequently lethal sickness, with a case casualty rate up to 90%. There are no authorized medications or antibody accessible for utilization in individuals or animals[1-3].

Virology of Ebola virus

The family Filoviridae is consist of two genera: MARV and EBOV. The Ebola virus family is further sub-partitioned into four different species: ICEBOV, REBOV, SEBOV and ZEBOV. EBOV particles contain a roughly 19kb single, negative stranded, linear noninfectious RNA genome. The genome codes seven structural & one non-structural protein with a gene order of: 3' step, nucleoprotein, virionprotein35 and 40, glycoprotein, Virionprotein30 and 24, polymerase protein and 5'trailer. Four proteins, NP, Vp30, Vp35 and genomic RNA in a RNP complex, while the three residual proteins (GP, Vp24, Vp40) are connected with the membrane[4-5]. GP is orchestrated as a forerunner molecule, GP0, which will be post translationally cleaved into two sub units, GP1 and GP2; these sub-units are connected by di-sulfide bond. Homotrimers of GP1–GP2 include the virion spikes and are the essential target of the host immune reaction. VP40 works as a matrix protein and help in formation of the filamentous particles, while VP24 is a minor viral protein whose functions stay obscure (Figure.1).



Figure.1 components of Ebola Virus Infection

Description:-

Irresistible Ebola virions are typically 920 nm long, 80 nm in measurement, and have a membrane pinched from the host cell by sprouting. The virus infection encodes for a nucleoprotein, a glycoprotein, 7 polypeptides, a polymerase, and 4 unknown proteins[6-9]. These proteins are produced using poly-adenylated mRNA interpreted in the host cell from the virus RNA (Figure.2).



Figure.2 Structure of EVD

Ebola virus infection is a biosafety level-4 pathogen and obliges extraordinary regulation measures and boundary protection, especially for human care experts. Ebola virus infections are profoundly transmissible by close contact with tainted blood, discharges, tissues, organs or living contaminated persons[10]. Communication through fomites that have been debased with bodily fluids is conceivable. Airborne transmission has not been recorded, and individual to-individual transmission is viewed as the central mode of transmission for human episodes paying little respect to how the record case was tainted. Internment ceremonies and treatment of dead bodies are known to assume an imperative part in transmission. Sexual transmission up to seven weeks after recuperation has been known for an alternate filo virus, Marburg virus, and the same is thought to be workable for Ebola virus infections. The danger for transmission is less in the early period of symptomatic patients (prodromal period)[11] .Ebola virus infections can easily survive in fluid or dried material for various days. Be that as it may, Ebola infection can be inactivated by UV radiation, gamma illumination, warming for 60 minutes at 60°C or bubbling for five minutes. The virus infection is powerless to sodium hypochlorite and disinfectants. Solidifying or refrigeration won't inactivate Ebola virus infection[12-13].

Nosocomial spread alludes to the spread of an ailment inside, a health care center or hospital. It happens as often as possible amid Ebola HF flare-ups. In African hospitals, sick patients are frequently tended to without the utilization of a veil, gown, or gloves. Exposure to the infection has happened when health care workers treated people with Ebola HF without wearing these sorts of defensive apparel. Likewise, when needles or syringes are utilized, they may not be of the disposable sort, or might not have been sterilized[14-15]. In the event that needles or syringes get to be sullied with virus infection and are then reused, various individuals can get to be contaminated(Figure .3).



Figure.3 Mechanism of replication of Ebola Virus

Diagnosis

Identifying Ebola HF in a person who has been contaminated for just a couple of days is troublesome, on the grounds that the early side effects, for example, red eyes and a skin rashes, are common to Ebola virus infection contamination and are seen regularly in patients with more ordinarily happening ailments[16-18].

On the other hand, if an individual has the early side effects of Ebola HF and there is motivation to accept that Ebola HF ought to be viewed as, the patient ought to be secluded and healthcare experts be advised. Specimen from the patient can then be gathered and tried to affirm contamination of Ebola Virus[19].

Lab test requirements at the time of ebola infection:

Timeline of infection	Diagnostic test available
Within a few days after symptoms begin	• Antigen-capture ELISA testing • IgM ELISA • Polymerase chain reaction (PCR) • Virus isolation
Later in disease course or after recovery	• IgM and IgG antibodies
Retrospectively in deceased patients	• Immunohistochemistry testing • PCR • Virus isolation

Vaccine development

A few animal models have been produced to investigate the pathogenesis of Ebola virus infection and to measure the viability of different antibody approaches. Guinea pigs & non-human mandrills speak to the essential animal models for antibody development in light of the fact that the progression and pathogenesis most nearly represent human ailment. A murine model was later created by serial section of virus infection in mice[20-23]. Despite the fact that the model permits the utilization of knockout and ingrained strains to assess hereditary determinants of virus infection, it is viewed as less prescient of human sickness on the grounds that it depends on a serially passaged, attenuated virus infection. While indications and time span of illness in guinea pigs equal those in people, non-human primate disease is viewed as the most prescient and helpful for antibody development[24].

Live attenuated virus infections and recombinant proteins have been utilized effectively as a part of a mixed bag of immunizations, however the safety & immunogenicity of gene based antibodies have demonstrated progressively appealing. Among the gene based methodologies, naked DNA has been utilized effectively in animal models to control the blend of immunogens inside the host cells and has demonstrated accommodating in various infectious disease.

While DNA antibodies have been exceedingly viable in rodents, their viability in non-human mandrills has been less effective. Preparing boosting inoculation protocol that utilize DNA vaccination emulated by boosting with pox virus infection vectors convey the gene for pathogen proteins have yielded drastically upgraded insusceptible reactions in animal studies, with 30 fold prominent increments in immune

response titer from the booster[25-27]. An alternate priming boosting methodology utilizing replication adeno virus infection for an Ebola virus infection immunization was tried in cynomolgus macaques. This study exhibited the unrivaled immunologic adequacy of this priming boosting consolidation for both cell and humoral immune reactions. These animal showed complete immune protection against a deadly test of infection, giving the first show of an Ebola infection immunization approach that secures mandrills against disease. In recent times, an accelerated inoculation has been produced that presents protection against a deadly infection challenge in non-human mandrills after a solitary vaccination. In the event that this antibody meets expectations correspondingly in people, it might be helpful in the regulation of intense episodes by ring inoculation[28].

An understanding of the components underlying Ebola infection actuated cytopathic impacts has encouraged the procedure of immunization and anti-viral treatment development, which has thusly given new clinical data regarding pathogenesis and the immune reaction. Ebola infection does not display the high level of inconsistency that other enveloped virus infections may utilize to avoid host immunity, yet Ebola virus infection GP modifies cell function and epitomizes an oval technique for safe avoidance that may have emerged through the development of Ebola infection with its host. The cytotoxic impacts of GP on macrophage & endothelial cell function disturb incendiary cell function and the respectability of the vasculature. Likewise, by changing the cell surface expression of attachment proteins and immune molecule, Ebola virus infection may upset methods discriminating to immune enactment and cytolytic T-cell function. These phenomena likely record for the dysregulation of the provocative reaction and the vascular brokenness character is Ebola infection disease, giving a reason to concentrating on GP as a focus for a preventative antibody and giving lead for other clinical intercessions[29-33].

Expert outlook

The utilization of rodents & non-human mandrills as precise and dependable models of human EBOV HF will be basic to the final assessment of candidate antibodies. A more intensive understanding of human EBOV HF is discriminatingly required to completely assess and compare the accessible animal models[34]. More exertion needs to be steered while assessing the malady pathogenesis amid the sporadic episodes in Africa utilizing cutting edge immunological & molecular techniques.

Obviously, rodents have not been exact in foreseeing the adequacy of EBOV antibody applicants in non-human mandrills. This group and others have exhibited that EBOV HF in non-human mandrills is more illustrative of human malady than EBOV contamination in rodents[35-37]. No EBOV antibody will be approved by regulatory authorities for human utilization in the event that it can't ensure non-human mandrills from clinical disease, viremia and demise.

There are basically two separate issues that must be tended in regards to the administration of EBOV HF that call for diverse clinical standards. To start with, in either a common flare-up or an episode connected with bioterrorism, a prompt reaction is required to contain the flare-up and prevent the spread of ailment to other geographic areas[38]. Up to this point, isolate practices have been powerful in constraining EBOV episodes however disease and mortality have been decimating in the isolated community and cutting edge progresses in worldwide travel don't guarantee that future flare-ups will be as effectively

contained. The accessibility of an immunization that could be quickly utilized to make a ring of inoculation around a plague zone will be discriminating to controlling ensuing spread of EBOV (Figure.4).

Figure.4 expert treating ebola infected patient

The second clinical ideal model that needs to be tended is long haul immunity that would be required for lab staff and healthcare personnel. We are unsure whether a solitary shot vaccination regimen will present long haul resistance immunity to EBOV. Also, adjuvants therapy might have value in enhancing efficacy of the adenovirus-based immunization strategies.

In the setting of bioterrorism, it is paramount to consider that biological executors may enter the body by means of a various route. Most antibodies are tried in animal models against a parenteral route; notwithstanding, the inhalation or vaporized route is the most critical to consider when arranging barriers against biological assaults. While the function of air genic transmission in EBOV flare-ups is obscure and thought to be extraordinary , EBOV is respectably steady in vaporized and between pen transmission, recommending intervention by little molecule mist concentrates, has been documented. Outstandingly, EBOV is profoundly irresistible by airborne exposure in rhesus monkey. Therefore, it will be paramount to demonstrate the viability of any candidate EBOV antibody against a various route of contamination to incorporate airborne exposure[39].

Right now, there are no accessible vaccine to treat EBOV infection. Immuno prophylaxis has been to a great extent incapable in animal models. Whereas passive immunization with killing monoclonal antibodies and hyper immune stallion serum has secured rodents from deadly EBOV disease, these antibodies failed to secure non-human mandrills from experiments with ZEBOV .Recently, there have been some investigation about the function of antibodies in upgrading EBOV contamination and conceivably fueling disease. While the importance of immunological development has yet to be recorded in vivo. Likewise with the different Immuno-treatments, anti-viral medications have additionally failed to improve the impacts of EBOV HF and once more, the vaccine that demonstrate some viability in rodents are insufficient in monkeys[40]. Current contemplates in research laboratory recommend that restorative regimens that focus on the sickness process as opposed to, or notwithstanding, viral replication may be the best approach for turning around the ailment course after exposure.

Acknowledgement:

I wish to thank the student for her critical discussion.

Conflicts of Interest Statement:

The Authors declare no conflicts of interest.

References:-

1. Donnelly, J. J., J. B. Ulmer, J. W. Shiver, and M. A. Liu. 1997. DNA vaccines. Annu. Rev. Immunol. 15:617–648.
2. Feldmann, H., H. Bugany, F. Mahner, H. D. Klenk, D. Drenckhahn, and H. J. Schnittler. 1996. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J. Virol. 70:2208–2214.
3. Feldmann, H., S. T. Nichol, H. D. Klenk, C. J. Peters, and A. Sanchez. 1994. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology 199:469–473.
4. Geisbert, T. W., P. Pushko, K. Anderson, J. Smith, K. J. Davis, and P. B. Jahrling. 2002. Evaluation in nonhuman mandrills of vaccines against Ebola virus. Emerg. Infect. Dis. 8:503–507.
5. Gupta, M., S. Mahanty, M. Bray, R. Ahmed, and P. E. Rollin. 2001. Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J. Virol. 75:4649–4654.
6. Ito, H., S. Watanabe, A. Sanchez, M. A. Whitt, and Y. Kawaoka. 1999. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J. Virol. 73:8907–8912.
7. Ito, H., S. Watanabe, A. Takada, and Y. Kawaoka. 2001. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J. Virol. 75:1576–1580.
8. Jahrling, P. B., J. Geisbert, J. R. Swearengen, G. P. Jaax, T. Lewis, J. W. Huggins, J. J. Schmidt, J. W. LeDuc, and C. J. Peters. 1996. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. 11(Suppl.):135–140.
9. Jahrling, P. B., T. W. Geisbert, D. W. Dalgard, E. D. Johnson, T. G. Ksiazek, W. C. Hall, and C. J. Peters. 1990. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 335:502–505.
10. Johnson, K. M., J. V. Lange, P. A. Webb, and F. A. Murphy. 1977. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet i:569–571.
11. Kilby, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. A. Nowak, G. M. Shaw, and M. S. Saag. 1998. Potent suppres- sion of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302–1307.
12. Kindzelskii, A. L., Z. Yang, G. J. Nabel, R. F. Todd III, and H. R. Petty. 2000. Ebola virus secretory glycoprotein (sGP) diminishes FcRIIIB-to-CR3 proximity on neutrophils. J. Immunol. 164:953–958.
13. Malashkevich, V. N., B. J. Schneider, M. L. McNally, M. A. Milhollen, J. X.Pang, and P. S. Kim. 1999. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A° resolution. Proc. Natl. Acad. Sci. USA 96:2662–2667.
14. Maruyama, T., L. L. Rodriguez, P. B. Jahrling, A. Sanchez, A. S. Khan, S. T. Nichol, C. J. Peters, P. W. Parren, and D. R. Burton. 1999. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 73:6024–6030.

15. Parren, P. W., T. W. Geisbert, T. Maruyama, P. B. Jahrling, and D. R. Burton. 2002. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J. Virol. 76:6408–6412.
16. Peters, C. J., and A. S. Khan. 1999. Filovirus diseases. Curr. Top. Microbiol. Immunol. 235:85–95.
17. Ploegh, H. L. 1998. Viral strategies of immune evasion. Science 280:248–253.
18. Sanchez, A., A. S. Khan, S. R. Zaki, G. J. Nabel, T. G. Ksiazek, and C. J. Peters. 2001. Filoviridae: Marburg and Ebola viruses, p. 1279–1304. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott, Williams & Wilkins, Philadelphia, Pa.
19. Sanchez, A., S. G. Trappier, B. W. J. Mahy, C. J. Peters, and S. T. Nichol. 1996. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. USA 93:3602–3607.
20. Sanchez, A., Z. Yang, L. Xu, G. J. Nabel, T. Crews, and C. J. Peters. 1998. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus.J. Virol. 72:6442–6447.
21. Schneider, J., S. C. Gilbert, T. J. Blanchard, T. Hanke, K. J. Robson, C. M. Hannan, M. Becker, R. Sinden, G. L. Smith, and A. V. Hill. 1998. Enhanced immunogenicity for CD8 T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397–402.
22. Simmons, G., J. D. Reeves, C. C. Grogan, L. H. Vandenberghe, F. Baribaud, J. C. Whitbeck, E. Burke, M. J. Buchmeier, E. J. Soilleux, J. L. Riley, R. W. Doms, P. Bates, and S. Pohlmann. 2003. DC-SIGN and DC-SIGNR bindEbola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 305:115–123.
23. Simmons, G., R. J. Wool-Lewis, F. Baribaud, R. C. Netter, and P. Bates. 2002. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 76:2518–2528.
24. Stro¨her, U., E. West, H. Bugany, H.-D. Klenk, H.-J. Schnittler, and H. Feldmann. 2001. Infection and activation of monocytes by Marburg and Ebola viruses. J. Virol. 75:11025–11033.
25. Sui, J., and W. A. Marasco. 2002. Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology 303:9–14.
26. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z.-Y. Yang, and G. J. Nabel. 2000. Development of a preventive vaccine for Ebola virus infection in mandrills. Nature 408:605–609.
26. Sullivan, N. J., T. W. Geisbert, L. Xu, Z.-Y. Yang, M. Roederer, R. A. Koup, P. B. Jahrling, and G. J. Nabel. 2003. Accelerated vaccination for ebola virus hemorrhagic fever in non-human mandrills. Nature 424:681–684.
27. Takada, A., S. Watanabe, H. Ito, K. Okazaki, H. Kida, and Y. Kawaoka. 2000. Downregulation of 1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 278:20–26.
28. Tighe, H., M. Corr, M. Roman, and E. Raz. 1998. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 19:89–97.
29. Vanderzanden, L., M. Bray, D. Fuller, T. Roberts, D. Custer, and K. Spik. 1998. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 246:134–144.
30. Villinger, F., P. E. Rollin, S. S. Brar, N. F. Chikkala, J. Winter, J. Sundstrom, S. R. Zaki, R. Swanepoel, A. Ansari, and C. J. Peters. 1999. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J. Infect. Dis. 179:S188–S191.
31. Volchkov, V. E., S. Becker, V. A. Volchkova, V. A. Ternovoj, A. N. Kotov, S. V. Netesov, and H. D. Klenk. 1995. GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214:421–430.
32. Volchkov, V. E., V. A. Volchkova, E. Muhlberger, L. V. Kolesnikova, M.Weik, O. Dolnik, and H.-D. Klenk. 2001. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291:1965–1969.
33. Watanabe, S., A. Takada, T. Watanabe, H. Ito, H. Kida, and Y. Kawaoka. 2000. Functional importance of the coiled-coil of the Ebola virus glycoprotein. J. Virol. 74:10194–10201.
34. Weissenhorn, W., A. Carfi, K. H. Lee, J. J. Skehel, and D. C. Wiley. 1998. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell 2:605–616.
35. Wilson, J. A., M. Hevey, R. Bakken, S. Guest, M. Bray, A. L. Schmaljohn, and M. K. Hart. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287:1664–1666.
36. Wyers, M., P. Formenty, Y. Cherel, L. Guigand, B. Fernandez, C. Boesch, and B. Le Guenno. 1999. Histopathological and immunohistochemical studies of lesions associated with Ebola virus in a naturally infected chimpanzee.J. Infect. Dis. 179:S54–S59.
37. Xu, L., A. Sanchez, Z. Yang, S. R. Zaki, E. G. Nabel, S. T. Nichol, and G. J.Nabel. 1998. Immunization for Ebola virus infection. Nat. Med. 4:37–42.
38. Yang, Z.-Y., H. J. Duckers, N. J. Sullivan, A. Sanchez, E. G. Nabel, and G. J.Nabel. 2000. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6:886–889.
39. Yang, Z.-Y., R. Delgado, L. Xu, R. F. Todd, E. G. Nabel, A. Sanchez, and G. J. Nabel. 1998. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 279:1034–1037.
40. Zaki, S. R., W. Shieh, P. W. Greer, C. S. Goldsmith, T. Ferebee, J. Katshitshi, F. Tshioko, M. Bwaka, R. Swanepoel, P. Calain, A. S. Khan, E. Lloyd, P.Rollin, T. G. Ksiazek, and C. J. Peters. 1999. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. J. Infect. Dis. 179:S36